News & Events

Date Title  
11/06/20
SAN DIEGO , Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for
08/13/20
SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement
07/30/20
SAN DIEGO , July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for
06/19/20
SAN DIEGO , June 19, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter
05/11/20
SAN DIEGO , May 11, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of
05/08/20
Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position SAN DIEGO , May 08, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric
04/28/20
Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA SAN DIEGO , April 28, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only
03/25/20
SAN DIEGO , March 25, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board
03/17/20
No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority SAN DIEGO, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss
02/27/20
SAN DIEGO , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for
02/20/20
Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™ SAN DIEGO , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company
02/13/20
SAN DIEGO , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its fourth quarter and
02/07/20
SAN DIEGO , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling